1. CTIM-26. PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA. (14th November 2022) Authors: Ahluwalia, Manmeet; Ciesielski, Michael J; Reardon, David A; Abad, Ajay; Curry, William; Wong, Eric; Peereboom, David; Figel, Sheila; Hutson, Alan; Groman, Adrienne; Withers, Henry; Liu, Song; Belal, Ahmed; Qiu, Jingxin; Mogensen, Kathleen; Schilero, Cathy; Khosla, Atulya; Casucci, Danielle; Mech... Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OTME-21. The role of Glioblastoma associated mesenchymal stem cells in immune suppression. (5th July 2021) Authors: Dharma, Sanam Sahjram; Barone, Tara; Figel, Sheila; Birkemeier, Meaghan; Zhang, Yali; Fenstermaker, Robert; Ciesielski, Michael Journal: Neuro-oncology advances Issue: Volume 3(2021)Supplement 2 Page Start: ii18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. TAMI-63. GLIOBLASTOMA ASSOCIATED MESENCHYMAL STEM LIKE CELLS (G-MSC) WHICH INFILTRATE TUMORS IN HUMAN AND MOUSE ARE STRONGLY ASSOCIATED WITH IMMUNOSUPPRESSION. (9th November 2020) Authors: Dharma, Sanam; Figel, Sheila; Barone, Tara; Ciesielski, Michael; Fenstermaker, Robert Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗